慢性炎症性脱髄性多発神経障害(CIDP)の成人に対するニポカリマブの有効性と安全性の研究
慢性炎症性脱髄性多発ニューロパチー(CIDP)の成人に投与されたニポカリマブの有効性と安全性を評価するための第2/3相、多段階、多施設、無作為化、二重盲検、プラセボ対照並行群離脱研究
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
アクセスの拡大
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
Colorado
-
Centennial、Colorado、アメリカ、80112
- 積極的、募集していない
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs、Florida、アメリカ、33067
- 完了
- Healthcare Innovations Institute Inc
-
Maitland、Florida、アメリカ、32751
- 完了
- Neurology Associates PA
-
Miami、Florida、アメリカ、33136
- 積極的、募集していない
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta、Georgia、アメリカ、30912
- 完了
- Augusta University
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 完了
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 完了
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- 完了
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak、Michigan、アメリカ、48073
- 完了
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64128
- 完了
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York、New York、アメリカ、10032
- 完了
- The Neurological Institute of New York
-
Patchogue、New York、アメリカ、11772
- 完了
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- 完了
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- 積極的、募集していない
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin、Texas、アメリカ、78756
- 完了
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- 積極的、募集していない
- Advocate Health - Aurora St. Luke's Medical Center
-
-
-
-
-
Buenos Aires、アルゼンチン、C1199ABB
- 積極的、募集していない
- Hospital Italiano de Buenos Aires
-
Buenos Aires、アルゼンチン、C1428AQK
- 募集
- Instituto Fleni
-
Buenos Aires、アルゼンチン、C1428
- 完了
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario、アルゼンチン、2900
- 募集
- INECO Neurociencias Orono
-
-
-
-
-
Birmingham、イギリス、B15 2TH
- 完了
- University Hospitals Birmingham NHS Foundation Trust
-
Devon、イギリス、EX2 5DW
- 完了
- Royal Devon & Exeter Hospital
-
Glasgow、イギリス、G514TF
- 積極的、募集していない
- NHS Greater Glasgow and Clyde
-
London、イギリス、NW3 2QG
- 完了
- Royal Free Hospital
-
Sheffield、イギリス、S10 2 JF
- 積極的、募集していない
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Catania、イタリア、95123
- 完了
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova、イタリア、16132
- 完了
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan、イタリア、20144
- 完了
- Casa di Cura del Policlinico
-
Milan、イタリア、20133
- 完了
- Istituto Neurologico Carlo Besta
-
Naples、イタリア、80131
- 積極的、募集していない
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano、イタリア、10043
- 完了
- Aou San Luigi Gonzaga
-
Pavia、イタリア、27100
- 完了
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma、イタリア、00168
- 完了
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano、イタリア、20086
- 完了
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Melbourne、オーストラリア、3004
- 完了
- The Alfred Hospital
-
Parkwood、オーストラリア、4215
- 完了
- Gold Coast University Hospital
-
-
-
-
-
Ottawa、カナダ、K1N 6N5
- 募集
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Athens、ギリシャ、12462
- 募集
- Attikon General Hospital of Athens
-
Athens、ギリシャ、11527
- 完了
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai、ギリシャ、26504
- 完了
- Patras University Hospital
-
Thessaloniki、ギリシャ、54636
- 募集
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Floridablanca、コロンビア、681004
- 完了
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín、コロンビア、50021
- 積極的、募集していない
- Instituto Neurológico de Colombia
-
-
-
-
-
Alicante、スペイン、03010
- 積極的、募集していない
- Hosp. Gral. Univ. de Alicante
-
Barcelona、スペイン、8035
- 完了
- Hosp Univ Vall D Hebron
-
Bilbao、スペイン、48013
- 積極的、募集していない
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian、スペイン、20014
- 完了
- Hosp. Univ. Donostia
-
Madrid、スペイン、28040
- 完了
- Hosp. Clinico San Carlos
-
Seville、スペイン、41009
- 積極的、募集していない
- Hosp. Virgen Macarena
-
-
-
-
-
Hradec Králové、チェコ、500 05
- 積極的、募集していない
- Fakultni nemocnice Hradec Kralove
-
Ostrava、チェコ、708 52
- 完了
- Fakultni Nemocnice Ostrava
-
Pardubice、チェコ、53203
- 完了
- Pardubicka krajska nemocnice a s
-
-
-
-
-
Berlin、ドイツ、13347
- 積極的、募集していない
- Judisches Krankenhaus Berlin
-
Bochum、ドイツ、44791
- 完了
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle、ドイツ、6120
- 積極的、募集していない
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover、ドイツ、30625
- 積極的、募集していない
- Medizinische Hochschule Hannover
-
Leipzig、ドイツ、4103
- 完了
- Universitaetsklinikum Leipzig
-
Potsdam、ドイツ、14471
- 完了
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
-
-
-
Bordeaux、フランス、33000
- 完了
- CHU Bordeaux
-
Bron、フランス、69699
- 完了
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre、フランス、94270
- 積極的、募集していない
- Hopital de Bicetre
-
Marseille、フランス、13385
- 積極的、募集していない
- Hopital de la Timone
-
Nice、フランス、06000
- 積極的、募集していない
- Hopital PASTEUR
-
Nîmes、フランス、30029
- 積極的、募集していない
- CHU Nimes Hopital Caremeau
-
Paris、フランス、75013
- 完了
- Hopital de la Pitie Salpetriere
-
Paris、フランス、75019
- 完了
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg、フランス、67200
- 積極的、募集していない
- CHRU Strasbourg
-
-
-
-
-
Almada、ポルトガル、2805-267
- 積極的、募集していない
- Hospital Garcia de Orta
-
Braga、ポルトガル、4710-243
- 完了
- Hospital de Braga
-
Porto、ポルトガル、4200 319
- 積極的、募集していない
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Chorzów、ポーランド、41 500
- 完了
- Centrum Medyczne
-
Krakow、ポーランド、30 539
- 完了
- Specjalistyczne Gabinety Lekarskie
-
Lublin、ポーランド、20 093
- 完了
- Prywatny Gabinet Lekarski
-
Poznan、ポーランド、61 731
- 積極的、募集していない
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Monterrey、メキシコ、64710
- 完了
- i Can Oncology Center
-
Tlalnepantla、メキシコ、54055
- 募集
- Clinical Research Institute S.C.
-
-
-
-
-
Beijing、中国、100191
- 完了
- Peking University Third Hospital
-
Beijing、中国、100034
- 完了
- Peking University First Hospital
-
Beijing、中国、100053
- 積極的、募集していない
- Xuanwu Hospital ,Capital Medical University
-
Beijing、中国、100070
- 積極的、募集していない
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun、中国、130021
- 積極的、募集していない
- The First Hospital of Jilin University
-
Changsha、中国、410008
- 完了
- Xiangya Hospital Central South University
-
Changsha、中国、410008
- 積極的、募集していない
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu、中国、610072
- 完了
- Sichuan Provincial Peoples Hospital
-
Chifeng、中国、024000
- 完了
- Chifeng Municipal Hospital
-
Fuzhou、中国、350001
- 積極的、募集していない
- Fujian Medical University Union Hospital
-
Guangzhou、中国、510080
- 積極的、募集していない
- The First Affiliated Hospital Sun Yat sen University
-
Jinan、中国、250012
- 積極的、募集していない
- Qilu Hospital of Shandong University
-
Jinan、中国、250014
- 完了
- Qianfoshan hospital of Shandong Province
-
Nanchang、中国、330006
- 積極的、募集していない
- The First Affiliated Hospital of NanChang University
-
Shanghai、中国、200336
- 完了
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai、中国、200040
- 積極的、募集していない
- Huashan Hospital Fudan University
-
Wuhan、中国、430023
- 完了
- Renmin Hospital of Wuhan University
-
Xi'an、中国、710032
- 完了
- Tangdu hospital the Fourth Military Medical
-
Xi'an、中国、710075
- 積極的、募集していない
- Xi 'an GaoXin Hospital
-
-
-
-
-
Kaohsiung City、台湾、88301
- 完了
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei、台湾、100
- 積極的、募集していない
- National Taiwan University Hospital
-
Taipei、台湾、111
- 積極的、募集していない
- Shin Kong Wu Ho Su Memorial Hospital
-
-
-
-
-
Asahikawa、日本、070-0901
- 積極的、募集していない
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City、日本、113 8519
- 積極的、募集していない
- Institute of Science Tokyo Hospital
-
Chiba、日本、260-8677
- 完了
- Chiba University Hospital
-
Hamamatsu、日本、430-8558
- 積極的、募集していない
- Seirei Hamamatsu General Hospital
-
Isehara、日本、259-1193
- 積極的、募集していない
- Tokai University Hospital
-
Kobe、日本、650 0047
- 完了
- Kobe City Medical Center General Hospital
-
Kodaira-shi、日本、187-8551
- 積極的、募集していない
- National Center of Neurology and Psychiatry
-
Koshigaya、日本、343-8555
- 積極的、募集していない
- Saitama Medical Center
-
Kumamoto、日本、860-8556
- 完了
- Kumamoto University Hospital
-
Nagoya、日本、466-8560
- 積極的、募集していない
- Nagoya University Hospital
-
Nagoya、日本、455-8530
- 積極的、募集していない
- Chubu Rosai Hospital
-
Osaka Sayama Shi、日本、589 8511
- 完了
- Kindai University Hospital
-
Sendai、日本、983-8520
- 積極的、募集していない
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun、日本、321 0293
- 完了
- Dokkyo Medical University Hospital
-
Shinjuku-ku、日本、162-8666
- 完了
- Tokyo Women's Medical University Hospital
-
Tenri、日本、632-0015
- 完了
- Tenri Hospital
-
Toon-shi、日本、791-0295
- 完了
- Ehime University Hospital
-
Toyama、日本、930-0194
- 完了
- Toyama University Hospital
-
Ube、日本、755-8505
- 完了
- Yamaguchi University Hospital
-
-
-
-
-
Seoul、韓国、05030
- 完了
- Konkuk University Medical Center
-
Seoul、韓国、02447
- 完了
- Kyunghee University Medical Center
-
Seoul、韓国、135-710
- 完了
- Samsung Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
他の名前:
|
|
プラセボコンパレーター:Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
時間枠:Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
時間枠:12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
時間枠:12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
時間枠:Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
時間枠:Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
時間枠:Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
時間枠:Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
時間枠:Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
時間枠:Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
時間枠:Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
時間枠:Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
時間枠:Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
時間枠:Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
時間枠:Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
時間枠:Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
時間枠:Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
時間枠:Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
時間枠:Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CR109195
- 80202135CDP3001 (その他の識別子:Janssen Research & Development, LLC)
- 2021-003234-37 (EudraCT番号)
- 2023-508425-28-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。